FDA DEVICE FACTS
Solana Bordetella Complete Assay
Quidel Corporation
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Solana Bordetella Complete Assay is an in vitro diagnostic test for the qualitative detection of Bordetella pertussis and Bordetella parapertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having respiratory tract infection attributable to Bordetella pertussis and Bordetella parapertussis. The Solana Bordetella Complete Assay is an HDA-based duplex assay that targets the IS481 and IS1001 sequence of Bordetella pertussis (BP) and Bordetella parapertussis (BPP) genomes, respectively. The IS481 sequence may also be found in strains of other organisms (i.e., B. holmesii and B. bronchiseptica). The IS1001 sequence may also be found in strains of other organisms (i.e., B. bronchiseptica). B. holmesii infection may cause clinical illness similar to B. pertussis, and mixed outbreaks involving both B. pertussis and B. holmesii infection have been reported. Additional testing should be performed if necessary to differentiate B. holmesii and B. pertussis. B. bronchiseptica is a rare cause of infection in humans. When clinical factors suggest that B. pertussis or B. parapertussis may not be the cause of respiratory infection, other clinically appropriate investigation(s) should be carried out in accordance with published guidelines. Negative results for the Solana Bordetella Complete Assay do not preclude B. pertussis or B. parapertussis infection and positive results do not rule out co-infection with other respiratory pathogens. Results from the Solana Bordetella Complete Assay should be used in conjunction with information obtained during the patient's clinical evaluation as an aid in diagnosis of B. pertussis and or B. parapertussis infection and should not be used as the sole basis for treatment or other patient management decisions.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。